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1. Summary 
Cats progressively infected with the gammaretrovirus feline leukemia virus (FeLV) are 
at high risk to die within a few months to years due to several disease symptoms that 
range from immune suppression, to anemia and lymphoma/ leukemia. Up to now, there 
is no specific drug available to treat FeLV infection. 
In the present study an in vivo experiment was performed to investigate if a short-term 
treatment with the integrase inhibitor raltegravir can effectively suppress FeLV 
replication, allowing the immune system to overcome the infection and therefore 
progressively infected cats to turn to a latent status (regressive infection). 
After demonstrating the high tolerance of raltegravir in three healthy specified pathogen-
free cats, seven progressively infected cats were treated during nine weeks (40 mg 
b.i.d. for 6.5 weeks and 80 mg b.i.d. for 2.5 weeks). A significant decrease in plasma 
viral RNA loads was observed, indicating the ability of raltegravir to reduce viral 
replication. However, a complete control of viremia was not achieved and only one cat 
showed a marginal antibody response against whole virus, which was probably 
insufficient to overcome the infection. Further investigations are needed to find an 
optimized treatment against FeLV, i.e. an ideal dosage, compound or combination of 
compounds has to be identified. 
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2. Zusammenfassung 
Für progressiv mit felinem Leukämievirus (FeLV) infizierte Katzen besteht ein hohes 
Risiko innerhalb von Monaten bis Jahren an den Folgen diverser 
Erkrankungserscheinungen wie Immunsuppression, Anämie oder Lymphomen/ 
Leukämie zu sterben. Bislang ist noch kein spezifisches Medikament erhältlich, um 
FeLV zu therapieren.  
In der aktuellen Studie wurde ein in vivo Experiment durchgeführt, um zu eruieren, ob 
eine Kurzzeittherapie mit dem Integrase Inhibitor Raltegravir die FeLV-Replikation  
effektiv unterdrücken kann, damit das Immunsystem die Infektion überwinden und 
progressiv infizierte Katzen zu einem latenten Status bringen kann (regressive 
Infektion).  
Nachdem eine sehr gute Verträglichkeit von Raltegravir bei drei gesunden spezifisch-
pathogen freien (SPF) Katzen gezeigt werden konnte, wurden sieben progressiv 
infizierte Katzen während neun Wochen behandelt (40 mg b.i.d. für 6.5 Wochen und 80 
mg b.i.d. für 2.5 Wochen). Es wurde ein signifikanter Rückgang der viralen RNA-Last im 
Plasma beobachtet, was für die Fähigkeit von Raltegravir spricht, die virale Replikation 
zu reduzieren. Eine vollständige Kontrolle der Virämie wurde allerdings nicht erreicht 
und nur eine Katze zeigte eine grenzwertige Antikörperantwort gegen das ganze Virus, 
welche vermutlich nicht ausreicht, um die Infektion zu überwinden.  
Weitere Untersuchungen sind notwendig, um eine optimale Therapie gegen FeLV zu 
finden, d. h. eine ideale Dosis, ein ideales Präparat oder eine Kombination von 
Präparaten. 
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3. Introduction 
Feline leukemia virus (FeLV) is a gammaretrovirus with worldwide distribution, affecting 
domestic cats and also some free-living felids, among them the Iberian lynx and the 
Florida puma (1-3). Of the four known outcomes of infection, progressive infection, 
regressive infection with or without antigenemia and abortive infection (4) , especially 
the persistently viremic cats (progressive infection) are at risk to die due to 
hematopoietic disorders, the consequences of immunodeficiency or fatal neoplasia (5). 
Although the prevalence seems to have decreased in Switzerland probably due to 
vaccination programs and a consistent management to detect infected cats (5), there 
are still countries with high prevalences (6-8). 
So far, there are no possibilities to treat FeLV infection with a specific medication. In 
one study, feline interferon omega was shown to inhibit FeLV in vitro and to have 
immunomodulatory activities, leading to an improvement of clinical scores and an 
extended survival time in vivo (9). However, there was no direct demonstration of 
antiviral effects in vivo; no viral parameters were measured throughout the study. In a 
recent clinical study on three FeLV-infected cats and seven cats infected with feline 
immunodeficiency virus, recombinant interferon omega seemed to have 
immunomodulatory properties, but no antiviral effect (10). In vivo treatment trials with 
the nucleoside analogue 3‘-azido-2‘,3‘-dideoxythymidine (AZT) showed an inhibitory 
effect, but high toxicity as well, which resulted, among others, in non-regenerative 
anemia (11). Recent antiretroviral agents emerging for the treatment of human 
immunodeficiency virus (HIV), namely the integrase strand transfer inhibitors raltegravir 
and elvitegravir, were tested in vitro against lentiviruses, alpha-, beta- and 
gammaretroviruses of different species (12). Raltegravir is the only integrase inhibitor so 
far available on the market, which exhibited good efficiency against gammaretroviruses. 
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It showed excellent inhibitory potential against the gammaretrovirus xenotropic murine 
leukemia-related retrovirus XMRV, a virus closely related to FeLV (13-15). An inhibitory 
effect on FeLV was also verified in three different feline cell lines with EC50 in the low 
nanomolar range, similar to what has previously been observed for HIV and XMRV (16). 
If effective, a treatment of viremic domestic cats with raltegravir would be of enormous 
advantage to alleviate the consequences of a progressive FeLV infection. However, due 
to financial and patient/ owner compliance considerations, the goal of the use of 
raltegravir in veterinary medicine has to be a temporally limited treatment, resulting in a 
complete recovery, even after treatment interruption. We speculate that when achieving 
a significant reduction of viral loads, the immune system of the cats may be able to 
overcome the viremia, turning the course of infection from progressive to regressive. 
Indeed, complete suppression of viral replication after a transient period of viremia of 
more than a year has been documented  in some cats (17), but these are very rare 
cases. A similar phenomenon was observed in some HIV patients, who were treated in 
an early phase of HIV infection. Probably due to the low viral reservoir in these patients, 
a full recovery of the infection was possible with no rebound of viremia even after 
treatment interruption (18). 
The aim of the present study was to assess the tolerance of raltegravir in domestic cats 
and the effect of a short-term treatment with raltegravir on the course of FeLV infection 
in progressively infected specified pathogen-free (SPF) cats, by monitoring the clinical 
outcome, as well as the FeLV antigen, proviral, viral and specific antibody load in these 
cats. 
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4. Materials and methods 
 
4.1. Treatment tolerance in healthy SPF domestic cats 
To investigate the feasibility of the administration of raltegravir and to better assess the 
potential side effects, we first tested the drug in uninfected healthy SPF cats with a 
dosage in the range used in humans, i.e. about 5-10 mg/kg twice daily (19). 
 
4.1.1 Raltegravir (IsentressTM) 
IsentressTM (raltegravir 400 mg film tabs, MSD Merck Sharp & Dohme AG, Luzern, 
Switzerland) was ground and re-encapsulated into smaller portions of 20 mg or 40 mg 
(Kantonsapotheke Zurich, Zurich, Switzerland). To facilitate the uptake by the cats, 
small gelatin capsules were used (14.4 x 5.1 mm, Inter Delta SA, Givisiez, Switzerland) 
and administered with the food twice daily. 
 
4.1.2 Animals 
Three healthy adult SPF cats (three to five years old, four to five kg of weight) were 
treated with 20 mg raltegravir b.i.d. during eight weeks followed by 40 mg b.i.d. for 
another seven weeks. 
All animal experiments were performed according to Swiss laws and were officially 
approved by the veterinary office on the canton Zurich (TVB 160/2010). The cats were 
kept in groups under etiologically and hygienically ideal conditions as described (20) 
and the SPF status of the cats was verified prior to the experiment as described 
previously (21). 
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4.1.3 Sample collection and processing 
Blood samples were collected under sedation (0.01 mg/kg midazolam, Dormicum®, 
Roche Pharma AG, Reinach, Switzerland) and 10 mg/kg ketamine, Narketan®, 
Vétoquinol AG, Belp, Switzerland) by jugular venipuncture using 5 ml syringes in weeks 
0, 1, 2, 4, 6, 8, 9, 10, 11, 13 and 15. Blood was immediately transferred into 
Ethylenediaminetetraacetic acid (EDTA)- and heparin-anticoagulated tubes and 
hematological (white blood cell count and differential, red blood cell count and size, 
hematocrit, hemoglobin concentration, mean cell hemoglobin, mean corpuscular 
hemoglobin concentration, platelet count) and clinical-chemical parameters (total 
bilirubin, plasma glucose, fructosamin, blood urea nitrogen, creatinin, protein (Biuret), 
albumin, cholesterin, triglycerides, alkaline phosphatase, amylase, lipase, aspartate 
aminotransferase, alanine aminotransferase, sodium, potassium, chloride, calcium, 
phosphate) were assessed, using standard methods of the clinical laboratory.  
The raltegravir plasma concentration of each time point was measured by high 
performance liquid chromatography- mass spectrometry at the University Hospital 
Zurich, Institute for Clinical Chemistry under conditions described (22). Heparin-
anticoagulated plasma from untreated cats was used as negative control. Plasma 
concentrations were also determined, after raltegravir administration has been omitted 
for 24h and 36h, to compare elimination rates of cats with those of humans (23). 
 
 
4.2 Treatment of SPF cats experimentally infected with FeLV 
4.2.1 Animals 
Eighteen, 14-16 weeks-old SPF male kittens (Liberty Research, Inc., Waverly, NY, 
USA) were kept under barrier conditions in two groups and the SPF status was verified 
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by testing blood, saliva and feces by PCR, RT-PCR and serology for absence of FeLV, 
FIV, feline parvo-, herpes-, corona-, calicivirus and feline hemotropic mycoplasmas as 
described (20). 
 
4.2.2 FeLV-A virus challenge 
Four aliquots of FeLV-A/ Glasgow 1 strain (24) stored at -80°C (kindly provided by 
Veterinary Diagnostic Services, School of Veterinary Medicine, College of Medical, 
Veterinary and Life Science, Glasgow University, Glasgow, UK) were thawed at 37°C, 
pooled (total: 17 ml, 1.1 x 106 FFU/ml) and the virus diluted on ice to 23 ml using RPMI 
cell culture medium (Invitrogen AG, Basel, Switzerland). Subsequently, 1 ml was 
aspired in a syringe and stored on ice until use.  
At the age of 19-21 weeks, each cat was infected intraperitoneally with 800‘000 FFU (in 
1 ml) of this virus. 
In week 6 post-infection a second virus challenge with 1.7 x 106 FFU (in 1.8 ml) was 
performed intraperitoneally in ten cats with only transient viremia. Origin and virus 
preparation was identical to the first challenge.  
 
4.2.3 Treatment 
Fifteen weeks after the first virus challenge, seven progressively infected cats were 
treated with 40 mg b.i.d. (corresponding to 10-15 mg/kg b.i.d.) raltegravir during six and 
a half weeks. Because none of the cats had cleared antigenemia by then, the dose was 
increased to 80 mg b.i.d. (20-25 mg/kg b.i.d.) for another two and a half weeks, starting 
in week 7 of the treatment. 
Historical data of previous experiments was used to compare the course of infection of 
untreated progressively infected cats with the seven treated cats of the present study. 
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For this experiment, IsentressTM was ground and re-encapsulated and the following 
gelatin capsules were used: 19.0 x 6.6 mm, containing 40 mg raltegravir, filled up with 
320 mg of lactose and 14.4 x 5.1 mm as described above (4.1.1). 
 
4.2.4 Sample collection and processing 
Blood samples were collected under sedation in weeks 0, 1, 2, 3, 4, 7, 8, 9, 10, 11, 12, 
13, 14, 15 post-infection (p.i.), in weeks 1, 2, 3, 4, 5, 6, 7, 8, 9 during the treatment and 
in weeks 1, 2, 4, 6, 8 post-treatment. Hematological and clinical-chemical parameters 
were assessed as described above (4.1.3). 
The raltegravir plasma concentration was measured in weeks 0, 3, 6, 9 of the treatment 
and in week 1 post-treatment (4.1.3). 
 
4.2.5 Detection of FeLV viral DNA in blood and viral RNA in plasma 
For determination of FeLV blood viral DNA loads, total nucleic acids (TNA) were 
extracted from a blood volume containing 106 white blood cells, or from a maximum 
volume of 100 μl, using the MagNa Pure LC Total Nucleic Acid Isolation Kit (Roche 
diagnostics AG, Rotkreuz, Switzerland) according to manufacturer’s instructions. All 
volumes were adjusted to 100 µl with phosphate-buffered saline (PBS). Negative 
controls consisting of 200 µl of PBS were concurrently prepared with each batch of 
samples to monitor for cross-contamination. The extracted TNA were analysed by real-
time PCR for FeLV DNA loads as described (25) on a ABI PRISM 7700/7500 sequence 
detection system (Applied Biosystems, Rotkreuz, Switzerland). PCR runs were 
performed with negative controls consisting of 5 µl of nuclease-free water. 
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TNA were extracted from 200 μl of plasma using the MagNa Pure LC Total Nucleic 
Isolation Kit according to manufacturer’s instructions and quantified by real-time RT-
PCR  for FeLV plasma viral RNA loads as described (25). 
 
4.2.6 Detection of FeLV virus antigen p27 by ELISA 
FeLV viremia was determined by p27 double antibody sandwich ELISA as described 
(26). All samples were tested in duplicates. Results were calculated as the percentage 
of a positive control (culture supernatant of FL-74 feline lymphoblastoid cell line 
permanently infected with FeLV), which was assayed with every plate. Values above 
4% were considered to be positive. In agreement with the European Pharmacopoeia 
(2005), a cat was designated as progressively infected when FeLV p27 antigen was 
positive for three consecutive weeks or on five occasions between weeks 3 and 15 p.i. 
 
4.2.7 Antibody Assays: FeLV whole virus and p45 antibody ELISAs 
The plasma samples were analysed for the presence of anti FeLV whole virus and anti 
FeLV p45 antibodies by ELISA, using 100 ng of p45/ well and 100 ng of gradient 
purified FL-74 FeLV with a dilution of 1:100 (whole virus ELISA) and 1:200 (p45 ELISA) 
as described (27, 28). In each assay pooled SPF sera (= negative control) and pooled 
sera collected from FeLV immune cats (= 100% positive control) were tested. Values 
above 25% of the positive control were considered to be positive.  
 
4.2.8 Statistics  
Statistical analyses were carried out using R software version 2.14.0 (the R Foundation 
for Statistical Computing, Vienna, Austria). Longitudinal effects (time) of the treatment 
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on viral RNA, viral DNA and p27 loads were compared by multivariate analysis of 
variance (MANOVA). A p-value < 0.05 was considered to be statistically significant. 
For the correlation analysis, the Spearman rank correlation test was used (pS), 
performed with Graph-Pad Prism (GraphPad Software, Version 3.0. San Diego, CA, 
USA). A p-value < 0.05 was again considered to be statistically significant. 
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5. Results 
5.1. Raltegravir-associated side effects in healthy SPF cats 
Cats showed neither changes in their behavior nor any clinical symptoms e.g. apathy, 
vomiting or diarrhea during the 15 weeks of treatment. The hematological and clinical-
chemical parameters remained unchanged and within the reference range. 
Raltegravir plasma concentrations ranged from 46 to 1040 nM at 20 mg b.i.d., and from 
151 to 1057 nM at 40 mg b.i.d. Plasma levels of raltegravir were almost undetectable 
after twenty-four hours (week 10) and thirty-six hours (week 11) of drug withdrawal.  
Both, 20 mg and 40 mg dosages, resulted in sufficient plasma concentrations to 
guarantee a good efficacy (at least 99% inhibition in vitro) (16). Relatively high 
differences in the raltegravir plasma concentrations between the cats and also a high 
variability between the respective time points were observed in all cats (Fig. 1).   
Because of the excellent tolerance and higher plasma concentration reached, we opted 
for the 40 mg regimen for the test in experimentally infected domestic cats. 
 
Fig. 1 Raltegravir plasma concentration (nM) of three adult SPF cats measured during a 
treatment period of 15 weeks.  
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Weeks 1-8: 20 mg raltegravir b.i.d. Weeks 9-15: 40 mg raltegravir b.i.d. 
Data points in weeks 10 and 11 represent plasma values after 24h and 36h of raltegravir 
withdrawal.  
Missing data in week 2 (cat B6) and in week 8 (cat J6) are due to the collection of high blood 
volumina in the beginning of the experiment and therefore a treatment-unrelated excessive 
decrease of the hematocrit (cat B6) and to anesthesia failure (cat J6). 
 
5.2. Treatment of SPF cats experimentally infected with FeLV 
5.2.1 FeLV infection outcome 
According to the results obtained by p27 ELISA, seven out of eighteen cats developed a 
persistent viremia (Fig. 2). Ten cats had a transient outcome of infection. All infected 
cats became FeLV provirus and viral RNA positive, indicating that FeLV infection had 
occurred in all of them (data not shown); one cat died four weeks p.i. with FeLV-related 
symptoms. Furthermore, there was no change in the infection-status after a second 
challenge of the ten cats, which induced only transient viremia. 
  
 
  
 
13 
 
Fig.2 Plasma FeLV p27 antigen loads of the seven viremic cats until week 15 p.i. The horizontal 
dotted/broken line represents the threshold for p27 positive results (≥ 4% of the positive control). 
 
5.2.2 Treatment outcome 
Raltegravir treatment of the seven progressively infected cats was started in week 15 
p.i. Because after six weeks of treatment (week 22 p.i.) no cat had turned completely 
negative for p27 antigen, a twofold higher dosage (80 mg b.i.d., corresponding to 20-25 
mg/kg) was administered to all seven cats for another two and a half weeks, starting in 
week 7. Although, such a high dosage has never been tested before, it was also well 
tolerated by the cats and no side effects were observed. FeLV p27 antigen loads, anti-
FeLV whole virus and p45 antibodies, as well as FeLV provirus and plasma viral RNA 
loads were determined to assess the inhibitory potential of the treatment (Fig. 3).  
In all seven cats, a significant correlation between the FeLV p27 antigen loads and the 
plasma viral RNA loads was observed (p<0.0001), (Fig. 4). 
Comparison with data from previous experiments using similar challenge doses 
(500’000 FFU) of the same virus in experimentally infected SPF cats (29) showed that 
treatment with raltegravir was effective in reducing viral RNA loads: pMANOVA= 0.048 for 
weeks 11, 15 (baseline), 17, 21 and 24 (treatment) p.i., pMANOVA= 0.031 for weeks 11, 
15 (baseline), 17 and 21 (treatment) p.i. The viral load reduction was approximately 
fivefold and became first apparent in week 5 of the treatment (Fig. 3b, Fig. 4, Table 1). 
Despite the high correlation between RNA and p27, the effect was only marginal for p27 
antigen: pMANOVA= 0.087 for weeks 11, 15 (baseline), 17, 21 and 24 (treatment) p.i., with 
two out of seven cats turning to nearly negative values (Fig. 3a). No effect by raltegravir 
was observed on provirus loads: pMANOVA= 0.668 for weeks 11, 15 (baseline), 17, 21 
and 24 (treatment) p.i. (Fig. 3c).  
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The anti FeLV p45 antibody levels remained below the threshold for positive results at 
any time point (data not shown). Only cat BP2 turned positive for anti FeLV whole virus 
antibodies in response to treatment (week 2 to 8 post-treatment, Fig. 3d). Cats CK5 and 
CR2 showed high anti FeLV whole virus antibody titers in week 4 p.i., but one week 
later they turned back to negative values again, with no change until the end of the 
experiment (Fig 3d).  
 
 
 
 
(a) 
  
 
15 
 
 
(b) 
 
  
(c) 
  
 
16 
 
  
(d) 
Fig.3 Plasma FeLV p27 antigen loads (a), viral RNA loads in plasma (b) and proviral DNA loads 
in blood (c) of the seven treated cats during the whole experiment. (d) Anti FeLV whole virus 
antibodies of the seven treated cats. The horizontal dotted/broken line represents the threshold 
for positive results (≥ 25% of the positive control). 
 
 
  
(a)                                                                (b) 
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(c)                                                                (d) 
 
   
(e)                                                                (f) 
 
(g) 
Fig. 4 Course of viral RNA and p27 loads for all cats plotted seperately (a-g: cat BP2, CC1, 
CK1, CK3, CK5, CP1, CR2, respectively). Treatment start was in week 15 p.i., interruption took 
place in week 24 p.i. 
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Table 1: Viral RNA load reduction compared to baseline (fold) of the seven progressively 
infected cats, during and after treatment. Gray cases highlight values > 3.0. WPI: weeks 
post-infection. BL: baseline  
 BL TREATMENT week INTERRUPTION week 
  1 2 3 4 5 6 7 8 9 1 2 4 6 8 
WPI 15 16 17 18 19 20 21 22 23 24 25 26 28 30 32 
BP2 1.0 1.1 1.8 2.1 3.5 3.4 15.2 6.3 13.3 7.6 6.8 13.1 8.8 5.1 4.7 
CC1 1.0 0.5 0.5 0.7 1.2 1.2 3.8 3.5 0.9 1.9 2.4 1.3 2.9 1.3 2.6 
CK1 1.0 0.5 0.6 0.4 1.2 1.2 2.0 3.1 0.8 1.6 2.1 1.5 0.7 0.2 1.4 
CK3 1.0 0.4 0.7 1.1 1.1 5.2 4.4 5.1 5.6 3.4 6.9 2.4 2.4 0.5 3.0 
CK5 1.0 0.7 0.8 0.9 1.9 8.3 4.1 3.7 5.2 4.9 6.4 1.7 1.5 0.9 0.7 
CP1 1.0 0.3 0.2 0.4 0.6 2.6 0.9 2.1 1.1 1.9 2.4 0.8 0.5 0.4 0.2 
CR2 1.0 0.7 1.6 1.9 1.9 13.4 5.7 26.2 6.8 5.6 7.6 2.4 0.7 0.8 3.1 
Mean 1.0 0.6 0.9 1.1 1.6 5.1 5.2 7.2 4.8 3.8 4.9 3.3 2.5 1.3 2.2 
St Dev 0.0 0.3 0.6 0.7 0.9 4.5 4.7 8.5 4.5 2.3 2.5 4.3 2.9 1.7 1.6 
 
 
5.2.2.1 Raltegravir plasma concentration 
Raltegravir plasma concentration ranged from 122 to 1413 nM at 40 mg b.i.d. and from 
655 to 1704 nM at 80 mg b.i.d. (Fig. 5). Cats CC1, CK1 and CK3 exhibited a high 
variability between the respective time points.  
One week after treatment interruption raltegravir was barely detectable (Fig. 5). 
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Fig. 5 Raltegravir plasma concentration (nM) of the seven progressively infected cats, 
measured in weeks 0, 3, 6 and 9 of the treatment and one week post-treatment (week 10). Time 
points 3 and 6 show the concentration where 40 mg raltegravir was administered twice daily, 
while week 9 corresponds to a twofold higher dosage (80 mg b.i.d.). 
 
 
5.2.3 Post-treatment outcome 
Raltegravir treatment was interrupted at the end of week 24 p.i. and the course of 
infection was monitored for another eight weeks. Plasma viral RNA loads started to 
increase again, returning to the same levels found prior to treatment within four weeks 
(Fig. 3b, Table 1), except for cat BP2, which exhibited the best overall response and 
was the only cat found positive for anti FeLV whole virus antibodies (Fig. 3d, Table 1). 
In this cat, RNA load reduction was still approximately fivefold at the end of the study, 
and p27 seemed to be decreasing as well. 
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6. Discussion 
The aim of the present study was to investigate whether the integrase inhibitor 
raltegravir has an inhibitory effect on FeLV in vivo, and if the magnitude of the inhibition 
enables cats to mount an adequate immune response, thus overcoming the 
consequences of the infection. For this purpose we first tested the drug in three healthy 
SPF cats, to ensure that raltegravir treatment does not cause severe side effects. The 
main metabolic pathway of raltegravir is by glucuronidation, well-known to be poor in 
domestic cats (30, 31). Hence, it was expected that tolerance to this drug may be worse 
than in humans or other species. However, the defective enzyme of glucuronidation in 
the cat (related to the absence of expression of UGT1A6) (30) is dissimilar to the 
enzyme mainly responsible for the glucuronidation of raltegravir (UGTA1) (23). 
Therefore, this metabolic defect in cats may not play a very important role for the 
elimination of raltegravir. Observations in other species confirmed an overall high 
tolerance to raltegravir. Dogs receiving raltegravir orally for one year at a dosage up to 
nine-fold above the 400 mg b.i.d. clinical dose (corresponding to ~360 mg/kg b.i.d.) 
used in humans did not show liver toxicity (19). Analogue results were seen in rats after 
six months of oral administration at up to 4.8-fold higher dosage than the 400 mg b.i.d. 
clinical dose (~2400 mg/kg) (19). In humans, twice the dosage (~12 mg/kg) is well 
tolerated (19) . These observations are consistent with our findings in SPF cats, where 
absolutely no side effects were observed during the whole period of 15 weeks, although 
we also administered a twofold higher dosage of 40 mg twice daily. Moreover, a fourfold 
higher dosage used for two and a half weeks in the major project was very well 
tolerated, too. In addition, a recent in vitro study showed, that raltegravir failed to induce 
toxicity even at concentrations 280-fold higher than the IC50 for antiviral activity in 
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Crandell Reese feline kidney cells (CrFK) (32), thus confirming the results obtained 
previously in our laboratory (16). 
To determine the effect of raltegravir in progressively infected cats, 18 kittens were 
infected intraperitoneally with 800’000 FFU FeLV-A Glasgow 1 strain. According to 
previous observations, 14 to 17 cats were expected to show a progressive infection (3, 
33-35). Unfortunately, only seven cats developed a progressive infection in the current 
study. An explanation for this unanticipated development may be a sudden drop in 
quality of the challenge virus. However, the virus, shipped in dry ice directly from the 
University of Glasgow a few days before experimental infection, was harvested, stored 
and the quality assessed under the same conditions as in previous experiments. 
Therefore, an extremely poor quality of the virus as a cause of the failure of obtaining 
enough progressively infected cats is rather unlikely, especially because already 50’000 
FFU are sufficient to cause a progressive infection in 8 of 10 cats, infected at the age of 
17-19 weeks (29). In addition, one cat died because of FeLV within a few weeks after 
infection, confirming that the virus stock used had a good infectivity. Alternatively, high 
endogenous FeLV loads in the cats may have been responsible for the poor 
progressive infection rate. Endogenous retroviruses can lead to partial resistance by 
receptor interference (36-38) and a similar effect has been hypothesized for FeLV as 
well (39), although not yet statistically validated. 
To achieve a higher number of progressively infected cats, a re-infection of the ten 
transiently viremic cats with 1.7 x 106 FFU FeLV-A Glasgow 1 strain was performed six 
weeks after the first challenge. Surprisingly, there was no change in the infection status, 
indicating an already developed protective immune response in these cats (40). 
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Based on the low number of treatable cats, there was no possibility to include an equal 
control group in this study. Therefore, we decided to treat all the progressively infected 
cats and to compare the outcome with historical data (29).  
During the nine weeks of treatment a decrease in plasma viral RNA loads was 
observed, indicating the ability of raltegravir to reduce viral replication. The decrease of 
plasma viral RNA loads was in the range of one log10 for four of the seven cats (Table 
1). In humans, raltegravir therapy achieved, in general, a higher decrease (at least 2 
log10), but this was always as a combination therapy (19), and the effect of raltegravir 
alone was difficult to discern. In three SIV-infected macaques, the effect was of around 
3 log10 reduction after four weeks treatment to undetectable levels (41). Thus, 
raltegravir seems to be less efficient in reducing replication in FeLV than in HIV or SIV-
infected individuals. RNA levels in FeLV-infected cats are in the range of 108-109 
copies/ml, while in the case of HIV and SIV the range is much lower: 103-105 copies/ml. 
Thus, viral reservoirs seem to be much more active for FeLV than for HIV/SIV, and this 
may explain the lower magnitude of the reduction in RNA loads. The non-significant 
change in p27 loads may be the consequence of the lower sensitivity of the test: only 
changes in p27 correlated with a much higher decrease in RNA loads may be 
statistically significant. 
As observed e.g. for SIV in macaques (41), viral DNA levels remained unchanged 
during treatment. This does not necessarily mean that the viral reservoir was unaffected 
by the treatment. The fivefold decrease in RNA loads shows that new cells are steadily 
infected in progressively infected cats even after RNA loads have reached a steady 
state. Integrase inhibitors do not prevent DNA synthesis, but only its integration into the 
host’s genome. Virus, infecting cells without integrating DNA, is unable to generate new 
RNA. Unchanged DNA levels may be due to the fact, that the qPCR test for FeLV is not 
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able to differentiate integrated (provirus) from unintegrated viral DNA. Nevertheless, 
once occurred, the integration process is irreversible. Therefore, treatment in the early 
phase of infection is really important, as exemplified in humans, where viral DNA levels 
were lower after treatment with raltegravir in HIV primary vs. chronic infection (42). 
 
Only in one cat (BP2) a marginal anti FeLV whole virus antibody response could be 
observed shortly after treatment interruption, but no anti p45 antibody response was 
detected in any cat at any time point. According to our knowledge, anti p45 antibodies 
are the most important to generate an effective immune response against FeLV (40). 
Anti FeLV whole virus antibodies can also protect from viremia, when titers are high 
enough and present for a longer period of time (> 3 months) (3). In this case, antibody 
concentrations of 27-28% of the positive control are a too low titer to change the course 
of infection and turn to a latent status in the time frame we monitored. Nevertheless, if 
persistent over a long time, the anti FeLV whole virus antibody response may lead to 
regressive infection, especially if combined with a continuation of the therapy, that 
would keep the viral replication at lower levels: cat BP2 was, indeed, the one that best 
responded to therapy in terms of RNA load reduction (Table 1), which was still 
approximately fivefold at 8 weeks after interruption of treatment. Therefore, long-term 
monitoring of this cat and, eventually, a continuation of the therapy will be crucial in 
determining if raltegravir treatment can, under some circumstances (e.g. cats with 
similar genetic background and/ or gene expression patterns), really induce a 
regressive infection. 
By week 4 after treatment interruption, plasma viral RNA loads had increased again in 
all seven cats, returning to the levels assessed before treatment in six of them. Although 
the short-term treatment was not sufficient to completely stop viremia, the course 
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observed after treatment interruption is clear evidence for an inhibitory effect of 
raltegravir.  
 
Further investigations are needed to better assess the effect of raltegravir. Although - 
based on the values of raltegravir plasma concentration - the use of a higher dosage is 
considered possible, there is no guarantee that a higher concentration in plasma and 
therefore a stronger effect of the treatment can be achieved. It seems that saturation 
occurred in some cats after administering the fourfold higher dosage of 80 mg b.i.d., 
leading to stable plasma concentrations. A variable genetic background and metabolism 
of each cat are presumably responsible for the inhomogeneous outcome. 
The development of novel integrase inhibitors opens the door to further interventions. 
Elvitegravir (43) and so called “new generation”- compounds like dolutegravir (S/GSK 
1349572) (44) or MK-2048 could be taken into account for further analyzes. MK-2048 
was examined in healthy humans, but is not yet available on the market (45). 
Dolutegravir is actually in phase ІІІ clinical trials (46). Lower dosages and probably a 
single-day administration are effective using this compound (47-49). In addition, a more 
intimate binding mode with the viral integrase compared to raltegravir and an improved 
resistance profile are beneficial (50). First, an in vitro examination in feline cells would 
be necessary to approve potentially similar qualities for the application in cats.  
Other classes of HIV drugs like protease inhibitors were shown to be ineffective against 
XMRV (14) and therefore rather ineligible for the use as an anti-FeLV drug. Reverse 
transcriptase inhibitors are problematic for the use in cats, because they are often only 
efficient near the cytotoxic threshold, as it also has been shown in vivo in cats treated 
with AZT or 9-(2-phosphonylmethoxyethyl) adenine (PMEA) (9).  
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Due to the fact, that a short-term treatment was not sufficient to completely stop viremia, 
a longer-term treatment like in HIV patients may be necessary also for cats to prevent 
death by progressive FeLV infection. Such a treatment is difficult to carry out, because 
the administration of capsules to cats is not always easy and the medicament plus the 
re-encapsulation are expensive and not affordable for everyone, since there is no 
specific veterinary market for these compounds.  
Nevertheless, the current study displays a first step into the right direction to achieve an 
effective treatment against FeLV with recent antiretroviral compounds. It is conceivable 
that future studies will explore the combination of several of them rather than single 
therapies. Indeed, a combination with peptide FeLV envelope inhibitors (51), immune 
system boosters like interferon omega (10) and CpG oligonucleotides (52, 53), drugs 
that can deplete early T-cell infection reservoirs (54, 55), and more efficient integrase 
inhibitors may be more effective in reducing viral replication than the individual 
compounds alone. Still, for the reasons mentioned above, the endpoint of a test of these 
compounds in vivo is not only the drastic reduction of viral loads, but the induction of a 
state of regressive infection in the cats through a short-term treatment of a few months. 
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7. Conclusion 
Although a short-term treatment with raltegravir is not sufficient to completely stop 
viremia in cats persistently infected with FeLV, a significant decrease in RNA loads 
indicates an influence on viral replication. An optimized treatment against FeLV, 
composed of the ideal dosage, compound or combination of compounds has to be 
identified in further investigations. 
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